149 related articles for article (PubMed ID: 32814642)
1. Impact of provider volume on front-line chemotherapy guideline compliance and overall survival in elderly patients with advanced ovarian cancer.
Aviki EM; Lavery JA; Roche KL; Cowan R; Dessources K; Basaran D; Green AK; Aghajanian CA; O'Cearbhaill R; Jewell EL; Leitao MM; Gardner GJ; Abu-Rustum NR; Sabbatini P; Bach PB
Gynecol Oncol; 2020 Nov; 159(2):418-425. PubMed ID: 32814642
[TBL] [Abstract][Full Text] [Related]
2. Impact of National Cancer Institute Comprehensive Cancer Centers on ovarian cancer treatment and survival.
Bristow RE; Chang J; Ziogas A; Campos B; Chavez LR; Anton-Culver H
J Am Coll Surg; 2015 May; 220(5):940-50. PubMed ID: 25840536
[TBL] [Abstract][Full Text] [Related]
3. Surgical outcomes and national comprehensive cancer network compliance in advanced ovarian cancer surgery in a low volume military treatment facility.
Phippen NT; Barnett JC; Lowery WJ; Miller CR; Leath CA
Gynecol Oncol; 2013 Oct; 131(1):158-62. PubMed ID: 23872110
[TBL] [Abstract][Full Text] [Related]
4. Observed-to-expected ratio for adherence to treatment guidelines as a quality of care indicator for ovarian cancer.
Galvan-Turner VB; Chang J; Ziogas A; Bristow RE
Gynecol Oncol; 2015 Dec; 139(3):495-9. PubMed ID: 26387962
[TBL] [Abstract][Full Text] [Related]
5. Impact of antibiotic treatment during platinum chemotherapy on survival and recurrence in women with advanced epithelial ovarian cancer.
Chambers LM; Kuznicki M; Yao M; Chichura A; Gruner M; Reizes O; Debernardo R; Rose PG; Michener C; Vargas R
Gynecol Oncol; 2020 Dec; 159(3):699-705. PubMed ID: 32950250
[TBL] [Abstract][Full Text] [Related]
6. A Risk-Adjusted Model for Ovarian Cancer Care and Disparities in Access to High-Performing Hospitals.
Bristow RE; Chang J; Villanueva C; Ziogas A; Vieira VM
Obstet Gynecol; 2020 Feb; 135(2):328-339. PubMed ID: 31923082
[TBL] [Abstract][Full Text] [Related]
7. Sociodemographic disparities in advanced ovarian cancer survival and adherence to treatment guidelines.
Bristow RE; Chang J; Ziogas A; Campos B; Chavez LR; Anton-Culver H
Obstet Gynecol; 2015 Apr; 125(4):833-842. PubMed ID: 25751200
[TBL] [Abstract][Full Text] [Related]
8. Trends in the receipt of guideline care and survival for women with ovarian cancer: A population-based study.
Warren JL; Harlan LC; Trimble EL; Stevens J; Grimes M; Cronin KA
Gynecol Oncol; 2017 Jun; 145(3):486-492. PubMed ID: 28372872
[TBL] [Abstract][Full Text] [Related]
9. Reasons for failure to deliver National Comprehensive Cancer Network (NCCN)-adherent care in the treatment of epithelial ovarian cancer at an NCCN cancer center.
Erickson BK; Martin JY; Shah MM; Straughn JM; Leath CA
Gynecol Oncol; 2014 May; 133(2):142-6. PubMed ID: 24517876
[TBL] [Abstract][Full Text] [Related]
10. Implementation of National Guidelines increased survival in advanced ovarian cancer - A population-based nationwide SweGCG study.
Dahm-Kähler P; Holmberg E; Holtenman M; Rådestad AF; Borgfeldt C; Hjerpe E; Marcickiewicz J; Bjurberg M; Tholander B; Hellman K; Kjølhede P; Högberg T; Rosenberg P; Åvall-Lundqvist E; Stålberg K
Gynecol Oncol; 2021 Apr; 161(1):244-250. PubMed ID: 33581846
[TBL] [Abstract][Full Text] [Related]
11. Delays from neoadjuvant chemotherapy to interval debulking surgery and survival in ovarian cancer.
Liu YL; Zhou QC; Iasonos A; Filippova OT; Chi DS; Zivanovic O; Sonoda Y; Gardner G; Broach V; OCearbhaill R; Konner JA; Aghajanian CA; Long K; Tew W
Int J Gynecol Cancer; 2020 Oct; 30(10):1554-1561. PubMed ID: 32522770
[TBL] [Abstract][Full Text] [Related]
12. Critical Analysis of Stage IV Epithelial Ovarian Cancer Patients after Treatment with Neoadjuvant Chemotherapy followed by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
Munoz-Zuluaga CA; Sardi A; Sittig M; Gushchin V; King MC; Nieroda C; Lopez-Ramirez F; Diaz-Montes TP
Int J Surg Oncol; 2020; 2020():1467403. PubMed ID: 33381312
[TBL] [Abstract][Full Text] [Related]
13. Increased disease-free and relative survival in advanced ovarian cancer after centralized primary treatment.
Palmqvist C; Staf C; Mateoiu C; Johansson M; Albertsson P; Dahm-Kähler P
Gynecol Oncol; 2020 Nov; 159(2):409-417. PubMed ID: 32943206
[TBL] [Abstract][Full Text] [Related]
14. Oncologic outcomes after splenectomy during initial cytoreductive surgery in advanced epithelial ovarian cancer: a nationwide population-based cohort study.
Said SA; van der Aa MA; Veldmate G; de Hullu JA; van Altena AM
Acta Obstet Gynecol Scand; 2022 Jan; 101(1):56-67. PubMed ID: 34719790
[TBL] [Abstract][Full Text] [Related]
15. Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer.
Chen JP; Huang QD; Wan T; Tu H; Gu HF; Cao JY; Liu JH
J Ovarian Res; 2019 Jul; 12(1):72. PubMed ID: 31362750
[TBL] [Abstract][Full Text] [Related]
16. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
[TBL] [Abstract][Full Text] [Related]
17. Adherence to European ovarian cancer guidelines and impact on survival: a French multicenter study (FRANCOGYN).
Jochum F; De Rozario T; Lecointre L; Faller E; Boisrame T; Dabi Y; Lavoué V; Coutant C; Touboul C; Bolze PA; Bricou A; Canlorbe G; Collinet P; Huchon C; Bendifallah S; Ouldamer L; Mezzadri M; Querleu D; Akladios C
Int J Gynecol Cancer; 2021 Nov; 31(11):1443-1452. PubMed ID: 34607855
[TBL] [Abstract][Full Text] [Related]
18. Impact of race, socioeconomic status, and the health care system on the treatment of advanced-stage ovarian cancer in California.
Long B; Chang J; Ziogas A; Tewari KS; Anton-Culver H; Bristow RE
Am J Obstet Gynecol; 2015 Apr; 212(4):468.e1-9. PubMed ID: 25448522
[TBL] [Abstract][Full Text] [Related]
19. Timing of surgery in patients with partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer.
Nitecki R; Fleming ND; Fellman BM; Meyer LA; Sood AK; Lu KH; Rauh-Hain JA
Gynecol Oncol; 2021 Jun; 161(3):660-667. PubMed ID: 33867146
[TBL] [Abstract][Full Text] [Related]
20. Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Chambers LM; Yao M; Morton M; Gruner M; Chichura A; Horowitz M; Costales AB; Rose PG; Michener CM; Debernardo R
Gynecol Oncol; 2021 May; 161(2):389-395. PubMed ID: 33551202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]